Use of Serum or Buffer-Changed EDTA-Plasma in a Rapid, Inexpensive, and Easy-To-Perform Hemolytic Complement Assay for Differential Diagnosis of Systemic Lupus Erythematosus and Monitoring of Patients with the Disease

ABSTRACT We previously described a simplified quantitative hemolytic assay for classical pathway (CP) hemolytic function in serum that has been shown to correlate with the 50% hemolytic complement (CH50) assay. In the present study, we used this assay to compare CP functions; plasma levels of C3, C4, and C3dg; and ratios of C3dg to C3 in healthy individuals and patients with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) with different degrees of complement activation. A significant depression in CP function and levels of C4 and C3 and increased C3dg levels and C3dg/C3 ratios were observed in the SLE patients. In patients with RA, CP function was normal, whereas C3, C4, and C3dg levels and the C3dg/C3 ratio were elevated. The SLE results are compatible with systemic complement consumption, whereas the RA data suggest an acute-phase reaction with a normal C3 catabolic rate. To facilitate the handling of patient samples, we also developed a method to restore the hemolytic function of EDTA-plasma by transferring it to Veronal-buffered saline containing the thrombin inhibitor lepirudin. This process inhibits coagulation and enables complement activation, allowing a longer time lag between sample harvesting and testing. These results, combined with previous correlation studies, suggest that the CP hemolytic assay can effectively replace the CH50 assay for routine SLE differential diagnosis and monitoring of disease activity.

[1]  J. Heremans,et al.  Immunochemical quantitation of antigens by single radial immunodiffusion. , 1965, Immunochemistry.

[2]  D. Mccarty.  Measurement of arthritic disease disability. , 1973, IMS, Industrial medicine and surgery.

[3]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[4]  A. Sjöholm,et al.  Homozygous deficiency of C4 in a child with a lupus erythematosus syndrome , 1982, Clinical genetics.

[5]  R. Maini,et al.  Measurement of the complement C3 breakdown product C3d by rocket immunoelectrophoresis. , 1982, Journal of immunological methods.

[6]  B. Gustavii,et al.  Complement components in 100 newborns and their mothers determined by electroimmunoassay. , 1983, Acta pathologica, microbiologica, et immunologica Scandinavica. Section C, Immunology.

[7]  D. Isenberg,et al.  The use of C3d as a means of monitoring clinical activity in systemic lupus erythematosus and rheumatoid arthritis. , 1983, Annals of the rheumatic diseases.

[8]  S. Bhakdi,et al.  Plasma C3d/C3 quotient as a parameter for in vivo complement activation. , 1984, Journal of immunological methods.

[9]  L. Truedsson,et al.  Inhibition of complement-mediated hemolysis in gel by rheumatoid factors. , 2009, Acta pathologica, microbiologica, et immunologica Scandinavica. Section C, Immunology.

[10]  B. Nilsson,et al.  Simplified assays of hemolytic activity of the classical and alternative complement pathways. , 1984, Journal of immunological methods.

[11]  A. Sjöholm,et al.  Sequential studies of complement activation in systemic lupus erythematosus. , 1985, Scandinavian journal of rheumatology.

[12]  A. Michael,et al.  Radioimmunoassay of the attack complex of complement in serum from patients with systemic lupus erythematosus. , 1985, The New England journal of medicine.

[13]  S. Abramson,et al.  Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease. , 1986, Arthritis and rheumatism.

[14]  M. Walport,et al.  Erythrocytes transfused into patients with SLE and haemolytic anaemia lose complement receptor type 1 from their cell surface. , 1987, Clinical and experimental immunology.

[15]  T. Lint,et al.  The terminal complement complex, C5b-9, a marker of disease activity in patients with systemic lupus erythematosus. , 1988, Arthritis and rheumatism.

[16]  J. Young,et al.  A semi-automated microassay for complement activity. , 1988, Journal of immunological methods.

[17]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[18]  P. Garred,et al.  Effect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation. , 1988, Clinical and experimental immunology.

[19]  M. Kirschfink,et al.  Binding and activation of C4 and C3 on the red cell surface by non-complement enzymes. , 1988, Molecular immunology.

[20]  A. Dalmasso.  Complement in laboratory medicine. , 1988, Complement and inflammation.

[21]  F. Arnett.  Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.

[22]  J. Clough,et al.  Effectiveness of testing for anti‐dna and the complement components ic3b, bb, and c4 in the assessment of activity of systemic lupus erythematosus , 1990, Journal of clinical laboratory analysis.

[23]  M. Walport,et al.  A study of in vivo immune complex formation and clearance in man. , 1990, Journal of immunology.

[24]  B. Morgan,et al.  Complement: Clinical Aspects and Relevance to Disease , 1991 .

[25]  B. Nilsson,et al.  Hereditary dysfunction of the third component of complement associated with a systemic lupus erythematosus-like syndrome and meningococcal meningitis. , 1992, Arthritis and rheumatism.

[26]  D. Sackett,et al.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.

[27]  B. Nilsson,et al.  Generation of iC3 at the Interface between Blood and Gas , 1992, Scandinavian journal of immunology.

[28]  E. Schned,et al.  Derivation of the SLEDAI. , 1993, Arthritis and rheumatism.

[29]  J. Köhl,et al.  Re-evaluation of the storage conditions for blood samples which are used for determination of complement activation. , 1995, Journal of immunological methods.

[30]  T. Jaskowski,et al.  Comparison of Three Different Methods for Measuring Classical Pathway Complement Activity , 1999, Clinical Diagnostic Laboratory Immunology.

[31]  U. Mårtensson,et al.  Complement activation in patients with systemic lupus erythematosus without nephritis. , 1999, Rheumatology.

[32]  B. Nilsson,et al.  Alterations in C3 activation and binding caused by phosphorylation by a casein kinase released from activated human platelets. , 1999, Journal of immunology.

[33]  G. Sturfelt,et al.  DNA levels in circulating immune complexes decrease at severe SLE flares-correlation with complement component C1q. , 1999, Journal of autoimmunity.

[34]  G. Sturfelt,et al.  Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies , 2000, Lupus.

[35]  B. Nilsson,et al.  Contact between a polymer and whole blood: sequence of events leading to thrombin generation. , 2001, The Journal of laboratory and clinical medicine.

[36]  John D Lambris,et al.  Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. , 2002, Blood.

[37]  J. Forslid,et al.  Repeated renal biopsy in proliferative lupus nephritis--predictive role of serum C1q and albuminuria. , 2002, The Journal of rheumatology.

[38]  T. Mollnes,et al.  Modern Complement Analysis , 2003, Clinical Diagnostic Laboratory Immunology.

[39]  M. Amigo,et al.  Increased Fibrin Polymerization Rate in Patients with Primary Antiphospholipid Syndrome and Systemic Lupus Erythematosus , 2003, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[40]  S. Krishnaswami,et al.  Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus. , 2004, Arthritis and rheumatism.

[41]  P. Horák,et al.  C1q complement component and -antibodies reflect SLE activity and kidney involvement , 2006, Clinical Rheumatology.

[42]  L. Truedsson,et al.  Complement and its breakdown products in SLE. , 2005, Rheumatology.

[43]  G. Jönsson,et al.  Hereditary C2 Deficiency in Sweden: Frequent Occurrence of Invasive Infection, Atherosclerosis, and Rheumatic Disease , 2005, Medicine.

[44]  M. Botto,et al.  Complement deficiencies in humans and animals: Links to autoimmunity , 2006, Autoimmunity.

[45]  John D Lambris,et al.  Generation of C5a in the absence of C3: a new complement activation pathway , 2006, Nature Medicine.

[46]  J. Ahearn,et al.  Cell-bound complement activation products (CB-CAPs) as a source of lupus biomarkers. , 2006, Advances in experimental medicine and biology.

[47]  C. Sáez,et al.  Circulating platelet-derived microparticles in systemic lupus erythematosus , 2005, Thrombosis and Haemostasis.